| Literature DB >> 21156740 |
Dirk Timmerman1, Lieveke Ameye, Daniela Fischerova, Elisabeth Epstein, Gian Benedetto Melis, Stefano Guerriero, Caroline Van Holsbeke, Luca Savelli, Robert Fruscio, Andrea Alberto Lissoni, Antonia Carla Testa, Joan Veldman, Ignace Vergote, Sabine Van Huffel, Tom Bourne, Lil Valentin.
Abstract
OBJECTIVES: To prospectively assess the diagnostic performance of simple ultrasound rules to predict benignity/malignancy in an adnexal mass and to test the performance of the risk of malignancy index, two logistic regression models, and subjective assessment of ultrasonic findings by an experienced ultrasound examiner in adnexal masses for which the simple rules yield an inconclusive result.Entities:
Mesh:
Year: 2010 PMID: 21156740 PMCID: PMC3001703 DOI: 10.1136/bmj.c6839
Source DB: PubMed Journal: BMJ ISSN: 0959-8138

Flow diagram of simple rules as triage test and subjective assessment by experienced ultrasound examiner as second stage test
Predictive value of each ultrasonic feature used in simple rules among masses for which simple rules yielded conclusive result (benign or malignant). Values are percentages (95% confidence interval); numbers
| Ultrasonic features | Predictive value |
|---|---|
| M1—Irregular solid tumour | 96 (88 to 98); 64/67 |
| M2—Presence of ascites | 97 (93 to 99); 157/162 |
| M3—At least four papillary structures | 88 (80 to 93); 75/85 |
| M4—Irregular multilocular solid tumour with largest diameter ≥100 mm | 84 (77 to 90); 103/122 |
| M5—Very strong blood flow (colour score 4) | 88 (82 to 92); 131/149 |
| At least one M feature | 87 (84 to 90); 340/389 |
| B1—Unilocular | 99 (98 to 99); 673/681 |
| B2—Presence of solid components, of which largest solid component has largest diameter <7 mm | 100 (90 to 100); 33/33 |
| B3—Presence of acoustic shadows | 95 (92 to 97); 223/234 |
| B4—Smooth multilocular tumour with largest diameter <100 mm | 99 (97 to 100); 190/191 |
| B5—No blood flow (colour score 1) | 98 (96 to 99); 615/629 |
| At least one B feature | 97 (96 to 98); 1083/1112 |
Rule 1: If one or more M features are present in absence of B feature, mass is classified as malignant.
Rule 2: If one or more B features are present in absence of M feature, mass is classified as benign.
Rule 3: If both M features and B features are present, or if no B or M features are present, result is inconclusive and second stage test is recommended.
Sensitivity and specificity of simple rules, subjective assessment, logistic regression models 1 and 2, and risk of malignancy index in cases in which simple rules yielded conclusive result (benign or malignant), stratified by menopausal status
| Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|
| Total (n=1501): | ||
| Simple rules | 92 (89 to 94) | 96 (94 to 97) |
| Subjective assessment | 91 (88 to 94) | 96 (94 to 97) |
| Logistic regression model 1 | 94 (91 to 96) | 92 (91 to 94) |
| Logistic regression model 2 | 95 (92 to 97) | 91 (89 to 92) |
| Premenopausal (n=969): | ||
| Simple rules | 91 (84 to 95) | 97 (95 to 98) |
| Subjective assessment | 90 (83 to 94) | 97 (96 to 98) |
| Logistic regression model 1 | 90 (83 to 94) | 96 (94 to 97) |
| Logistic regression model 2 | 92 (85 to 96) | 95 (93 to 96) |
| Postmenopausal (n=532): | ||
| Simple rules | 93 (89 to 95) | 92 (89 to 95) |
| Subjective assessment | 91 (87 to 94) | 90 (86 to 93) |
| Logistic regression model 1 | 96 (93 to 98) | 83 (78 to 87) |
| Logistic regression model 2 | 97 (93 to 98) | 77 (72 to 82) |
| Total (n=1147): | ||
| Simple rules | 92 (89 to 95) | 95 (93 to 96) |
| Subjective assessment | 91 (87 to 93) | 95 (93 to 96) |
| Logistic regression model 1 | 94 (91 to 96) | 91 (89 to 93) |
| Logistic regression model 2 | 95 (93 to 97) | 89 (87 to 91) |
| Risk of malignancy index | 75 (71 to 80) | 95 (93 to 96) |
| Premenopausal (n=688): | ||
| Simple rules | 91 (84 to 95) | 96 (94 to 98) |
| Subjective assessment | 90 (83 to 95) | 97 (95 to 98) |
| Logistic regression model 1 | 90 (83 to 95) | 94 (92 to 96) |
| Logistic regression model 2 | 92 (85 to 96) | 94 (92 to 96) |
| Risk of malignancy index | 55 (45 to 64) | 96 (94 to 97) |
| Postmenopausal (n=459): | ||
| Simple rules | 93 (88 to 95) | 92 (87 to 95) |
| Subjective assessment | 91 (87 to 94) | 90 (86 to 94) |
| Logistic regression model 1 | 96 (93 to 98) | 81 (76 to 86) |
| Logistic regression model 2 | 97 (94 to 98) | 78 (72 to 83) |
| Risk of malignancy index | 84 (79 to 88) | 91 (87 to 94) |
Sensitivity and specificity of subjective assessment, logistic regression models 1 and 2, and risk of malignancy index in cases in which simple rules yielded inconclusive result, stratified by menopausal status
| Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|
| Total (n=437): | ||
| Subjective assessment | 89 (83 to 93) | 80 (75 to 84) |
| Logistic regression model 1 | 88 (83 to 92) | 47 (41 to 53) |
| Logistic regression model 2 | 80 (74 to 86) | 50 (44 to 56) |
| Premenopausal (n=227): | ||
| Subjective assessment | 84 (74 to 91) | 85 (78 to 90) |
| Logistic regression model 1 | 81 (71 to 89) | 64 (56 to 71) |
| Logistic regression model 2 | 70 (58 to 79) | 63 (55 to 70) |
| Postmenopausal (n=210): | ||
| Subjective assessment | 92 (85 to 96) | 73 (64 to 80) |
| Logistic regression model 1 | 93 (87 to 97) | 21 (15 to 30) |
| Logistic regression model 2 | 87 (80 to 92) | 30 (22 to 39) |
| Total (n=357): | ||
| Subjective assessment | 89 (83 to 93) | 78 (72 to 83) |
| Logistic regression model 1 | 89 (83 to 93) | 44 (38 to 51) |
| Logistic regression model 2 | 82 (75 to 87) | 48 (42 to 55) |
| Risk of malignancy index | 50 (42 to 58) | 84 (78 to 88) |
| Premenopausal (n=182): | ||
| Subjective assessment | 84 (73 to 91) | 83 (75 to 88) |
| Logistic regression model 1 | 84 (73 to 91) | 63 (54 to 71) |
| Logistic regression model 2 | 74 (62 to 83) | 63 (54 to 71) |
| Risk of malignancy index | 32 (22 to 45) | 87 (79 to 92) |
| Postmenopausal (n=175): | ||
| Subjective assessment | 92 (84 to 96) | 71 (61 to 80) |
| Logistic regression model 1 | 93 (86 to 97) | 20 (13 to 29) |
| Logistic regression model 2 | 88 (79 to 93) | 28 (19 to 38) |
| Risk of malignancy index | 63 (52 to 72) | 80 (71 to 87) |
Sensitivity and specificity of strategy in which simple rules are used as triage test and subjective assessment, logistic regression model 1 or 2, or risk of malignancy index is used in tumours for which simple rules yield inconclusive result, and sensitivity and specificity of using subjective assessment, logistic regression model 1 or 2, or risk of malignancy index in all tumours
| Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|
| Simple rules + subjective assessment | 91 (88 to 93) | 93 (91 to 94) |
| Simple rules + logistic regression model 1 | 91 (88 to 93) | 86 (84 to 88) |
| Simple rules + logistic regression model 2 | 88 (85 to 91) | 87 (85 to 89) |
| Simple rules + inconclusive=“malignant”* | 95 (92 to 96) | 78 (75 to 80) |
| Subjective assessment | 90 (88 to 93) | 93 (91 to 94) |
| Logistic regression model 1 | 92 (90 to 94) | 84 (82 to 86) |
| Logistic regression model 2 | 90 (88 to 93) | 83 (81 to 85) |
| Simple rules + subjective assessment | 91 (88 to 93) | 92 (90 to 93) |
| Simple rules + logistic regression model 1 | 91 (88 to 93) | 85 (82 to 87) |
| Simple rules + logistic regression model 2 | 89 (86 to 91) | 85 (83 to 88) |
| Simple rules + risk of malignancy index | 79 (75 to 83) | 93 (91 to 94) |
| Simple rules + inconclusive=“malignant”* | 95 (92 to 96) | 76 (73 to 78) |
| Subjective assessment | 90 (87 to 92) | 92 (90 to 93) |
| Logistic regression model 1 | 93 (90 to 95) | 81 (79 to 84) |
| Logistic regression model 2 | 91 (88 to 93) | 81 (79 to 83) |
| Risk of malignancy index | 68 (63 to 72) | 93 (91 to 94) |
*Cases in which simple rules yielded inconclusive result are classified as malignant.
Ability of simple rules to classify tumours with different histology as benign or malignant. Values are numbers (percentages)
| Pathology | Total No | Conclusive diagnosis using simple rules | Correctly classified if simple rules yielded conclusive result |
|---|---|---|---|
| Benign: | 1396 | 1132/1396 (81) | 1083/1132 (96) |
| Endometrioma | 400 | 347/400 (87) | 339/347 (98) |
| Teratoma | 226 | 211/226 (93) | 211/211 (100) |
| Simple cyst + parasalpingeal cyst | 131 | 122/131 (93) | 122/122 (100) |
| Functional cyst | 77 | 62/77 (81) | 62/62 (100) |
| Hydrosalpinx + salpingitis | 49 | 37/49 (76) | 34/37 (92) |
| Peritoneal pseudocyst | 11 | 11/11 (100) | 11/11 (100) |
| Abscess | 24 | 13/24 (54) | 10/13 (77) |
| Fibroma | 81 | 44/81 (54) | 34/44 (77) |
| Serous cystadenoma | 236 | 181/236 (77) | 170/181 (94) |
| Mucinous cystadenoma | 138 | 91/138 (66) | 81/91 (89) |
| Rare benign | 18 | 10/18 (56) | 8/10 (80) |
| Uterine fibroid | 5 | 3/5 | 1/3 |
| Borderline: | 111 | 56/111 (50) | 45/56 (80) |
| Borderline serous stage I | 55 | 33/55 (60) | 25/33 (76) |
| Borderline serous stage II | 3 | 0/3 | – |
| Borderline serous stage III | 8 | 4/8 | 3/4 |
| Borderline mucinous stage I | 41 | 16/41 (39) | 14/16 (88) |
| Borderline mucinous stage IV | 1 | 1/1 | 1/1 |
| Borderline endometroid stage I | 1 | 0/1 | – |
| Rare borderline | 2 | 2/2 | 2/2 |
| Primary invasive: | 373 | 275/373 (74) | 259/275 (94) |
| Primary invasive stage I | 70 | 46/70 (66) | 45/46 (98) |
| Primary invasive stage II | 30 | 20/30 (67) | 19/20 (95) |
| Primary invasive stage III | 202 | 157/202 (78) | 149/157 (95) |
| Primary invasive stage IV | 30 | 24/30 (80) | 23/24 (96) |
| Rare primary invasive | 41 | 28/41 (68) | 23/28 (82) |
| Metastatic | 58 | 38/58 (66 ) | 36/38 (95) |